NCT02293005View on ClinicalTrials.gov

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 20, 2015

Primary Completion Date

July 6, 2021

Study Completion Date

July 6, 2021

Conditions
Lung CancerMesothelioma
Interventions
DRUG

Alisertib

50 mg twice a day on Days 1-7 of each 21-day study cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02293005 - Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | Biotech Hunter | Biotech Hunter